StockNews.com Initiates Coverage on Chimerix (NASDAQ:CMRX)

Equities research analysts at StockNews.com initiated coverage on shares of Chimerix (NASDAQ:CMRX) in a report released on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on CMRX. Wedbush reaffirmed a “neutral” rating and set a $8.55 price objective (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright reaffirmed a “neutral” rating and set a $8.55 price target (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 price objective (down from $10.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Stock Down 0.1 %

Shares of NASDAQ CMRX opened at $8.50 on Monday. The stock’s 50-day simple moving average is $6.04 and its two-hundred day simple moving average is $3.23. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.53. The firm has a market capitalization of $797.33 million, a P/E ratio of -9.04 and a beta of 0.32.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. As a group, research analysts anticipate that Chimerix will post -0.99 EPS for the current fiscal year.

Insider Activity at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

Large investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. boosted its stake in shares of Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after purchasing an additional 496,823 shares during the period. Stoneridge Investment Partners LLC raised its holdings in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 8,134 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in Chimerix during the 4th quarter valued at $2,626,000. Valeo Financial Advisors LLC grew its holdings in Chimerix by 78.8% in the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after acquiring an additional 64,420 shares during the last quarter. Finally, Palumbo Wealth Management LLC purchased a new position in shares of Chimerix in the fourth quarter valued at about $221,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.